Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy targets Hard-to-Treat lung cancer

NCT ID NCT07206498

Recruiting now Disease control Sponsor: Wayshine Biopharm, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called WSD0922-FU combined with the standard drug osimertinib for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). The trial aims to see if the combination is safe and can shrink tumors. About 48 adults whose cancer has progressed on previous treatment or has spread to the brain will participate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
WSD0922-FU combined with osimertinib (Tagrisso)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced lung cancer that has stopped responding to standard therapy or has spread to the brain.
What could go wrong
This is an early-phase trial with only 48 participants, so the benefits and risks are not yet well understood. The drug combination may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai East Hospital

    RECRUITING

    Shanghai, 200123, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.